Meanwhile, other new therapies outside the JAK inhibitor class are also making waves in the AD market, notably Sanofi’s injectable antibody Dupixent (dupilumab) and Pfizer’s topical PDE-4 ...

The application of PDE4 inhibitors appears to be a promising option to facilitate with minimal side effects the spontaneous passage of (distal) ureteral stones and relieve pain associated with ...

However, none of the PDE4 inhibitors tested so far has reached the market, mainly owing to tolerability issues such as emesis. A study in Nature Biotechnology that sheds light on the structural ...